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Dopamine (D2) receptor antagonists have formed the
mainstay of treatment for psychotic disorders for more
than four decades. Therapy has traditionally been limited
to phenothiazine and butyrophenone derivatives such as
chlorpromazine and haloperidol, the actions of which are
thought to be mediated by blockade of D2 receptors [1, 2.].
Although these conventional antipsychotic agents usually
improve the positive symptoms of schizophrenia and help
to prevent relapse, they have only a marginal effect on
negative symptoms [3.], cognitive impairment [4.], and
mood disturbances [5, 6.], all of which are common in
patients with schizophrenia. Moreover, these agents are
typically associated with a high incidence of extra-
pyramidal symptoms, parkinsonism, tardive dyskinesia
[7.], and other side-effects.
Clozapine, which is structurally distinct from conven-
tional antipsychotics, was the ®rst member of a novel
group of antipsychotic agents to improve psychotic
symptoms with minimal risk of extrapyramidal symptoms
[8.]. However, its clinical usefulness is limited by its
potential to cause agranulocytosis in approximately 1% of
patients, which has largely restricted its use to the
treatment of treatment-resistant schizophrenia.
The clinical effectiveness of clozapine is postulated to be
related to relatively weak D2 receptor af®nity and potent
serotonin (5-HT)2A receptor antagonism. This has, in part,
led to the hypothesis that antagonism of serotonin
receptors in the brain and a high 5-HT2A/D2 binding
af®nity ratio limits the emergence of extrapyramidal
symptoms, and, at the same time, improves ef®cacy in
negative symptoms of schizophrenia [8, 9.].
Since the discovery of clozapine, several novel
antipsychotic agents have been developed. The potential
bene®ts that these novel agents may offer include: broader
spectrum of symptom improvement, fewer or no
extrapyramidal symptoms, minimal risk of tardive dyski-
nesia, and reduction or absence of prolactin elevation and
related side-effects. Although the novel antipsychotics
share certain features, their pharmacology is diverse,
predicting functional differences, many of which have
been observed in clinical trials. Thus, there are notable
differences in the side-effect pro®les of the various atypical
antipsychotics [10±13.], and some differences are beginning
to develop in the ef®cacy pro®les for these agents.
Ziprasidone is a novel antipsychotic in late-stage
clinical development. It is chemically distinct from
clozapine and has a unique receptor pro®le that
distinguishes it from other antipsychotic agents. Both
in vitro and in vivo studies indicate that the af®nity of
ziprasidone for 5-HT2A receptors is an order of
magnitude greater than its af®nity for D2 receptors
[14.]. Ziprasidone also acts as a potent 5-HT1A receptor
agonist, is a potent 5-HT1D and 5-HT2C receptor
antagonist, and moderately inhibits 5-HT and noradre-
naline (NA) reuptake sites, actions which are thought to
predict ef®cacy in reducing positive and negative
symptoms of schizophrenia and associated symptoms of
depression and anxiety, as well as having a low liability
for inducing movement disorders [5, 15±18.]. In
addition, ziprasidone has negligible cholinergic (m1)
activity and only modest af®nities for histaminic (H1)
and a1-adrenoceptors, which predict low liability for
cognitive impairment, sedation, and anticholinergic and
cardiovascular side-effects [11, 12.]. The pharmacology of
ziprasidone also suggests a low propensity for some of
the nonmotor side-effects of certain newer antipsycho-
tics. Ziprasidone is a relatively less potent human a1-
adrenoceptor antagonist (relative to D2) than several of
the other novel antipsychotics, suggesting that it may be
less likely to cause orthostatic hypotension. The 5-HT
and NA reuptake inhibition, the potent 5-HT1A agonist
activity and the reduced H1 and a1 af®nity compared
with other antipsychotics may also offset the appetite
stimulation and weight gain linked to 5-HT2C receptor
antagonist activity, and are believed to contribute to the
low potential for weight gain associated with ziprasidone
compared with other novel antipsychotics [19, 20.].
An extensive clinical trials program has investigated the
short-term use of oral ziprasidone in acutely ill patients
with schizophrenia or schizoaffective disorder, and long-
term use in stable patients with chronic or subchronic
schizophrenia (the Ziprasidone Extended Use in Schizo-
phrenia [ZEUS] trial). These studies have con®rmed the
therapeutic and tolerability advantages of ziprasidone over
conventional antipsychotics. In the ZEUS study, ziprasi-
done treatment resulted in a lower probability of acute
exacerbation over a 1-year period with continuing
improvements in overall psychopathology and negative
symptoms, compared with placebo [21.]. Global function
also improved over this time period. In several aspects,
ziprasidone may offer ef®cacy and tolerability advantages
over other novel antipsychotics as well.
Correspondence: Dr R. Tandon, University of Michigan Medical Center,
Department of Psychiatry, Ann Arbor, Michigan, USA.
f 2000 Blackwell Science Ltd Br J Clin Pharmacol, 49 (Suppl. 1), 1S±3S 1S
The pharmacokinetics of ziprasidone have been char-
acterized in both healthy volunteers and patients with
schizophrenia. The papers presented in this supplement
describe the pharmacokinetic and drug interaction pro®les
of ziprasidone. Studies have shown that ziprasidone exhibits
linear and predictable pharmacokinetics and has a low
potential for drug interactions. Administration with food
increases the absorption of ziprasidone up to 100%, and
when taken with food, the average absolute bioavailability is
approximately 60% [22.]. Ziprasidone is highly protein-
bound (>99%). Ziprasidone is metabolized extensively
with less than 1% of an oral dose excreted unchanged in
urine and faeces.Human livermicrosomes, probe substrates,
and recombinant enzyme studies show CYP3A4 to be the
primary isozyme responsible for the metabolism of
ziprasidone [23.]. The major metabolites formed are
ziprasidone-sulfoxide and ziprasidone-sulphone. Both
metabolites are clinically inactive. With multiple dosing,
peak serum ziprasidone levels are observed at 6±8 h
postdose. The mean half-life is about 7 h, suggesting that
twice-daily dosing is appropriate, and steady-state plasma
concentrationsof ziprasidone are attainedwithin1±3 daysof
the initiation of oral therapy. At steady-state, systemic
exposure is dose-proportional over the 20±80 mg twice-
daily dose range. Age, gender, and mild or moderate renal or
hepatic impairment have no clinically signi®cant in¯uence
on ziprasidone exposure. Thus, dose adjustment may not be
needed in the elderly or in those with mild ormoderate renal
or hepatic impairment.
Ziprasidone has little potential for interaction with
drugs metabolized by cytochrome P450, or to inhibit
CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.
Co-administration of ziprasidone with other CYP3A4
substrate inhibitors or inducers does not appear to be
problematic. In addition, no clinically signi®cant interac-
tions have been reported with lithium, combined oral
contraceptives, or combined aluminium and magnesium
hydroxide antacid.
In summary, ziprasidone is a novel antipsychotic with a
unique array of pharmacological activities that predict a
broad range of bene®cial effects, as well as a low liability for
inducing movement disorders, cardiovascular side-effects,
sedation, and cognitive impairment. Ziprasidone exhibits
linear and predictable pharmacokinetics and has a low
potential for drug interactions. Overall, ziprasidone appears
to offer important therapeutic and tolerability advantages
over conventional, and some novel, antipsychotics.
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